Kiromic Biopharma, Inc.’s Post

Theralase Technologies (TSXV: TLT) CEO Roger DuMoulin-White joined Steve Darling from Proactive to share details of an update on the company's Phase II Non-Muscle Invasive #BladderCancer clinical study during an interview with Steve Darling from Proactive. DuMoulin-White shared the significant findings from the study, revealing that it has provided the primary study treatment to 63 patients. The interim clinical data from Study II shows promising results, with a Complete Response (CR) rate of 54% at 6 months, 38% at 12 months, and 37% at 15 months. These CR rates surpass the guidelines set by the International Bladder Cancer Group (IBCG). Additionally, at the 90 Day Assessment Visit, 56% of Evaluable Patients achieved a CR, and 63% achieved a Total Response (CR + IR). At 450 days, 37% achieved a CR, and 41% achieved a TR. Watch at #Proactive #ProactiveInvestors #TSXV #OTCQB #TLT #TLTFF http://ow.ly/YLin10598yw

Initial PEGASUS trial results presented today at #ESMO2023 suggest the Guardant Reveal ctDNA blood test may be used to guide adjuvant treatment of patients with high-risk stage II or stage III colon cancer to reduce unnecessary toxicity from chemotherapy and improve the response to standard chemotherapy regimens. PEGASUS is the first clinical utility trial for tissue-free detection of minimal residual disease. https://bit.ly/3MfeutU #liquidbiopsy

NEW from #ASCO2024 | Phase I trial of SX-682, a CXCR1/2 inhibitor, in #metastaticmelanoma 🎥 🇺🇸 Sapna Patel, BA, MD, The University of Texas MD Anderson Cancer Center, remarks on a Phase I trial (NCT03161431) examining SX-682, a CXCR1/2 inhibitor, in combination with #pembrolizumab in patients with metastatic #melanoma resistant to anti-PD-1 therapy 🌟 Patients received increasing doses of SX-682, with primary endpoints focusing on #safety and #tolerability, and secondary endpoints including #objectiveresponserate (ORR) and #overallsurvival (OS) 🌟 The results indicated a tolerable safety profile and encouraging #clinical activity, with a notably longer median OS in this cohort Learn more 👉 https://lnkd.in/ersjX-4f #VJOncology #Oncologynews

This content is intended for U.S. audiences only.     At the upcoming #ASCO24, we’re presenting more than 100 abstracts across multiple tumor types, including data from three pivotal Phase III trials, including two back-to-back #Lungcancer plenaries and a late-breaking special session in #Breastcancer: bit.ly/3KaeVnE    Visit the link to read more about our aim to:  - Transform treatment expectations across earlier-stage #Lungcancer settings   - Redefine outcomes across subtypes and stages of #Breastcancer   - Advance the next wave of medicines and combination therapies to attack cancer from multiple angles 

JUST IN: A groundbreaking targeted treatment, zolbetuximab, has shown promising results in extending survival for patients with advanced gastric or gastroesophageal junction cancer. The FDA has granted priority review to its biologic license application, marking a significant milestone in the fight against this challenging disease. Patients expressing a specific biomarker may benefit from this new therapy. Let's hope for its approval and improved survival rates! #MedicalAdvancement #CancerTreatment #GastricCancer #FDAReview To learn more and read the complete story, click on this link. https://lnkd.in/gprDkC87

A significant day today as inobrodib publishes in Cancer Cell. Huge well done and thank you to the whole, wider team. Press release, with quotes from Tim Somervaille, Emma Searle and Leif Bergsagel, is here: https://lnkd.in/e4hjxH9X The paper confirms inobrodib’s differentiated mechanism of action, displacing p300/CBP from key super-enhancer sites in tumour cells. This impacts the expression of MYC and IRF4, which translates into the clinical activity seen in multiple myeloma (MM) in particular. We believe that displacing and not degrading the targets, is what gives inobrodib its therapeutic window, with some patients remaining on drug over 1.5yrs. Publication: https://lnkd.in/ewZa-i3i Many thanks to our clinical investigators, healthcare teams and collaborative scientists, consultants and CROs. Luciano Nicosia Emma Searle Leif Bergsagel #multiplemyeloma

Meet our team at the Society for Immunotherapy of Cancer (SITC). We will also present two posters: -Poster # 760: an update from our Phase 1/2 ABILITY Study including anti-tumor activity, safety, pharmacokinetic and pharmacodynamic data following treatment with MDNA11, a long-acting, beta-enhanced IL-2 Superkine. -Poster # 1071: pre-clinical data for MDNA113, a novel first-in-class tumor-targeted and tumor-activated bifunctional anti-PD1-IL-2 superkine, will also be presented at the conference. #Superkines #Cytokines #EngineeredCytokines #immunotherapy #ImmunoOncology

Fabhalta (iptacopan) is the first and only FDA-approved oral monotherapy for adults with Paroxysmal Nocturnal Haemoglobinuria (PNH) Iptacopan is a Factor B inhibitor that acts proximally in the alternative pathway of the complement system. It represents a novel approach to complement inhibition that can help deliver comprehensive hemolysis control (IVH and EVH). Fabhalta Prescribing Information https://lnkd.in/eeVxRkjM PNH: When blood machinery goes wrong https://lnkd.in/exhnpKKA Hemolytic processes in PNH and its treatment: intravascular and extravascular hemolysis https://lnkd.in/ekTYPWPd Understanding PNH https://lnkd.in/efemYqJF #PNH #Fabhalta #iptacopan #Moffitt #MoffittCancerCenter Moffitt Cancer Center

Cancer is a fibrotic disease—and the FDA issued a Letter of Support for the inclusion of our PRO-C3 biomarker in tumor fibrosis studies. Active tumor fibrosis is the leading factor in cold, dense, hypoxic, and collagen-rich tumors. Watch Nicholas Willumsen, Director of Oncology at Nordic Bioscience, discuss how the FDA's endorsement may impact clinical decision-making and patient outcomes. PRO-C3 is measured on the Roche Diagnostics cobas® e automated platform, increasing robustness and accuracy in sample measurements and enabling future in-vitro diagnostic (IVD) use. Morten Karsdal Christina Jensen Neel Ingemann Nissen Jeppe Thorlacius-Ussing Claus S. von Arenstorff Daniel Gabor #FDA #DrugDevelopment #TumorFibrosis #CancerReserach #ClinicalTrials

The news is out! 🌟 We're thrilled to announce that we've been selected to present in an oral Minisymposium during the upcoming #AACR24 Annual Meeting. Our presentation will showcase two of our predictive PROphet® tools, which can be used independently or in combination for advanced #NSCLC patients: 1️⃣ One to guide treatment decisions by assessing a patient's probability of benefiting from immune-checkpoint inhibitor (ICI) therapy. 2️⃣ Another to assess the likelihood of patients experiencing severe immune-related adverse events (irAEs). "These findings are a source of great excitement for us, with our main commitment to bringing these advancements to healthcare providers and patients, improving cancer care globally." - Ofer Sharon, MD, CEO of OncoHost Read the full news release here: https://prn.to/4c3ZSZG Attending #AACR and want to meet? Schedule here: https://bit.ly/49VX5zF #Proteomics #CancerResearch #Biomarkers #BiomarkerDevelopment #PrecisionOncology #LCSM